

# AMP

## PIPELINE



Your European B2B Partner

# LIST OF APIs IN PIPELINE

February 2019

ADVANCED STAGE	THERAPEUTIC AREA	EU DMF readiness	US DMF readiness	Other Documentation
1. Apixaban	Blood & blood forming organs	✓	031166	
2. Apremilast	Musculo-skeletal system	✓	031141	
3. Baricitinib	Antineoplastic & immunomodulating agents	Q3 2019	Q3 2019	
4. Bazedoxifene acetate*	Musculo-skeletal system	✓	031793	
5. Brexpiprazole	Nervous system	✓	032347	
6. Dabigatran etexilate mesylate	Blood & blood forming organs	✓	027620	Chinese DMF - under registration
7. Dapagliflozin	Alimentary tract & metabolism	✓	030555	Korean DMF
8. Dapagliflozin Propanediol Monohydrate <b>NEW!</b>	Alimentary tract & metabolism	✓	033387	
9. Empagliflozin	Alimentary tract & metabolism	✓	033180	
10. Linagliptin	Alimentary tract & metabolism	✓	029844	Chinese DMF
11. Oxcarbazepine <b>NEW!</b>	Nervous system	Technical file in Q1 2019		
12. Pimavanserin tartrate	Nervous system	✓	033385	
13. R-baclofen hydrochloride <b>NEW!</b>	Musculo-skeletal system	✓	033383	
14. Rivaroxaban	Blood & blood forming organs	✓	027661	Chinese DMF
15. Sacubitril/Valsartan complex	Cardiovascular system	✓	032337	
16. Safnamide methanesulfonate*	Nervous system	Q2 2019	Q2 2019	
17. Saxagliptin hydrochloride	Alimentary tract & metabolism	Pilot plant scale & DMF preparation upon request		
18. Saxagliptin monohydrate base	Alimentary tract & metabolism	✓		
19. Solifenacin <b>NEW!</b>	Genito-urinary system & sex hormones	✓	024044	
20. Ticagrelor	Blood & blood forming organs	✓	028674	

EARLY DEVELOPMENT	THERAPEUTIC AREA	EU DMF/US DMF
1. Elagolix sodium <b>NEW!</b>	Genito-urinary system & sex hormones	
2. Linaclotide	Alimentary tract & metabolism	DMF preparation upon request
3. Ozanimod	Antineoplastic & immunomodulating agents	
4. Siponimod	Antineoplastic & immunomodulating agents	
5. Sotagliflozin	Alimentary tract & metabolism	Q1 2020
6. Sitagliptin hydrochloride <b>NEW!</b>	Alimentary tract & metabolism	Q1 2020

\*product not covered by a compound patent in the territory of Poland

## DISCLAIMER

The above list is presented solely for informational purposes and does not constitute an offer in any sense. Products under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.

## CONTACT

**POLPHARMA GROUP  
PHARMACEUTICAL WORKS**  
Pelplińska 19  
83-200 Starogard Gdański  
Poland  
phone: +48 58 563 16 00

**SALES**  
phone: +48 58 563 21 22  
+48 58 563 21 26  
+48 22 364 64 11  
e-mail: salesb2b@polpharma.com  
www.polpharmab2b.com

**MARKETING**  
phone: +48 22 364 63 25  
e-mail: marketingb2b@polpharma.com  
www.api.polpharma.com

Meet us on LinkedIn:

**LinkedIn**®

www.linkedin.com/  
company/polpharma-b2b